These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Human health consequences of use of antimicrobial agents in aquaculture. Heuer OE; Kruse H; Grave K; Collignon P; Karunasagar I; Angulo FJ Clin Infect Dis; 2009 Oct; 49(8):1248-53. PubMed ID: 19772389 [TBL] [Abstract][Full Text] [Related]
46. Antimicrobial resistance: cost and containment. Coast J; Smith RD Expert Rev Anti Infect Ther; 2003 Aug; 1(2):241-51. PubMed ID: 15482119 [TBL] [Abstract][Full Text] [Related]
47. Antimicrobial Pharmacokinetics and Pharmacodynamics. Jarrell AS; Kruer RM; Johnson D; Lipsett PA Surg Infect (Larchmt); 2015 Aug; 16(4):375-9. PubMed ID: 26207398 [TBL] [Abstract][Full Text] [Related]
48. The place of quinolones in bacterial infections. Neu HC Adv Intern Med; 1991; 36():1-32. PubMed ID: 2024577 [TBL] [Abstract][Full Text] [Related]
49. The choice of antimicrobial drugs. Med Lett Drugs Ther; 1990 May; 32(817):41-8. PubMed ID: 2185399 [No Abstract] [Full Text] [Related]
50. High-dose intravenous fluoroquinolones in the treatment of severe infections. Modai J J Chemother; 1999 Dec; 11(6):478-85. PubMed ID: 10678789 [TBL] [Abstract][Full Text] [Related]
51. Multidisciplinary antimicrobial management teams: the way forward to control antimicrobial resistance in hospitals. Struelens MJ Curr Opin Infect Dis; 2003 Aug; 16(4):305-7. PubMed ID: 12861082 [No Abstract] [Full Text] [Related]
52. [New quinolones: similarities and differences]. Levi GC AMB Rev Assoc Med Bras; 1989; 35(5):202-6. PubMed ID: 2486418 [TBL] [Abstract][Full Text] [Related]
53. Quinolone antimicrobial agents. Neu HC Annu Rev Med; 1992; 43():465-86. PubMed ID: 1580602 [TBL] [Abstract][Full Text] [Related]
54. Limitations of MIC as the sole criterion in antimicrobial drug dosage regimen design: the need for full characterization of antimicrobial pharmacodynamic profile especially for drug-resistant organisms. Gehring R; Riviere JE Vet J; 2013 Oct; 198(1):15-8. PubMed ID: 24025153 [No Abstract] [Full Text] [Related]
55. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Lipsky BA; Holroyd KJ; Zasloff M Clin Infect Dis; 2008 Dec; 47(12):1537-45. PubMed ID: 18990064 [TBL] [Abstract][Full Text] [Related]
56. ECDC adds new pages to online directory on infection prevention and control. Eurosurveillance editorial team Euro Surveill; 2015 May; 20(18):. PubMed ID: 25990236 [No Abstract] [Full Text] [Related]
57. [Pay attention to optimizing antimicrobial therapy in critically ill children with severe infection]. Xu F; Dang HX Zhonghua Er Ke Za Zhi; 2011 Jan; 49(1):1-3. PubMed ID: 21429302 [No Abstract] [Full Text] [Related]
58. [Fluoroquinolones--a current review]. Christ W; Kemmler H Med Monatsschr Pharm; 2001 Jul; 24(7):215-25. PubMed ID: 11486553 [No Abstract] [Full Text] [Related]
59. Principles of antimicrobial therapy: what should we be using? Southwood LL Vet Clin North Am Equine Pract; 2006 Aug; 22(2):279-96, vii. PubMed ID: 16882476 [TBL] [Abstract][Full Text] [Related]
60. [Criteria for the clinical evaluation of antimicrobial drugs in neonates]. Fujii R; Sato Y; Kobayashi H; Nishimura T; Sunagawa K; Iwata K; Meguro E; Toyonaga Y; Akita H; Iwai N; Motohiro K; Sato H Jpn J Antibiot; 1996 Jul; 49(7):743-53. PubMed ID: 8828074 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]